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  Abstract 
    Objectives.   Brain-derived neurotrophic factor (BDNF) is involved in major depressive disorder and neurodegenerative 
diseases. Clinical studies, showing decreased serum BDNF levels, are difﬁ  cult to interpret due to limited knowledge of 
potential confounders and mixed results for age and sex effects. We explored potential determinants of serum BDNF 
levels in a community sample of 1230 subjects.   Methods.   Multiple linear regression analyses with serum BDNF level as 
the dependent variable were conducted to explore the effect of four categories of potential BDNF determinants (sampling 
characteristics, sociodemographic variables, lifestyle factors and somatic diseases) and of self-reported depressive symptoms 
(Beck  ’  s Depression Inventory (BDI).   Results.   Our results show that BDNF levels decline with age in women, whereas in 
men levels remain stable. Moreover, after controlling for age and gender, the assays still showed lower serum BDNF levels 
with higher BDI sum scores. Effects remained signiﬁ  cant after correction for two main confounders (time of sampling and 
smoking), suggesting that they serve as molecular trait factors independent of lifestyle factors.   Conclusions.   Given the age  –
  sex interaction on serum BDNF levels and the known association between BDNF and gonadal hormones, research is 
warranted to delineate the effects of the latter interaction on the risk of psychiatric and neurodegenerative diseases.   
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Introduction 
  Brain-derived neurotrophic factor (BDNF) belongs 
to the neurotrophin family of growth factors and 
regulates aspects of neural plasticity of neurons 
in multiple brain regions (Mossner et al. 2007). 
Signiﬁ  cant concentrations of BDNF are also found 
in peripheral blood (Brunoni et al. 2008; Sen et al. 
2008). In animals high correlations between cerebral 
BDNF expression and peripheral serum-BDNF 
levels have been shown (Karege et al. 2002b), 
suggesting a comparable relationship in humans. 
Along these lines, BDNF levels in humans have been 
linked to a wide variety of brain diseases, among 
which neuropsychiatric (Nakazato et al. 2003; Binder 
and Scharfman 2004; Hashimoto et al. 2004, 2006; 
Gratacos et al. 2007; Machhado-Vieira et al. 2007; 
Ikeda et al. 2008) and neurodegenerative diseases 
(Azoulay et al. 2005; Yasutake et al. 2006). 
  Two recent meta-analyses conﬁ  rmed signiﬁ  cantly 
lower serum BDNF levels for depressed patients 
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  The present study was designed to do so: we 
looked for determinants of serum BDNF levels in a 
large community sample of middle-aged and elderly, 
with a particular emphasis on potential associations 
with age, sex and depressive symptoms.     
  Methods   
  Study population 
  The present study sample was drawn from the 
Nijmegen Biomedical Study (NBS), a population-
based survey of people aged between 20 and 90 years. 
For details we refer to a previous publication 
(Hoogendoorn et al. 2006). A total of 2253 respon-
dents were then invited to participate in a study of 
non-invasive measurements of atherosclerosis of 
whom 1517 gave their informed consent. They sub-
sequently visited the hospital for measurements and 
blood sampling, as described in detail elsewhere 
(Holewijn et al. 2009). This latter group was hence 
eligible for participation in the present study. The 
only exclusion criterion was the use of antidepressant 
medication, as this has consistently been associated 
with BDNF levels and might mask the effect of other 
determinants (Brunoni et al. 2008; Sen et al. 2008). 
  In accordance with the Declaration of Helsinki the 
study protocol was approved by The Medical Ethics 
Committee of the Radboud University Nijmegen 
Medical Centre and informed, written consent was 
obtained from all participants.     
  Serum BDNF 
  Following the baseline assessment and ranging from 
9 to 44 months after having been drawn, serum 
samples were sent to the Department of Psychiatry 
and Neuropsychology in Maastricht (The Nether-
lands) for BDNF measurement, where they were 
stored at   –  80  °  C. Serum BDNF protein levels were 
measured within three months after their receipt 
using the Emax Immuno Assay system from Pro-
mega according to the manufacturer  ’  s protocol. The 
undiluted serum was acid treated, which in a dilu-
tion-dependent way reliably increased the detectable 
BDNF. Subsequently, serum samples were diluted 
100 times and stored again at   –  80  °  C for BDNF assay 
the next day. After dilution, the BDNF levels were 
well within the range of the standard curve. The 
assay sensitivity threshold was ascertained at 1.56 
ng/ml reﬂ  ecting the minimum level of BDNF in the 
serum that could be reliably determined. In our pilot 
study we had found that BDNF levels of acid-treated 
samples with subsequent dilution the day preceding 
the BDNF assay did not differ from the levels 
obtained in samples following acid treatment only 
relative to the concentrations found in healthy con-
trols, with levels normalizing after treatment with 
antidepressants (Brunoni et al. 2008; Sen et al. 
2008). The studies included in the meta-analyses 
were restricted to clinically depressed patients, most 
of whom were women. As experimental ﬁ  ndings sug-
gest that alterations in BDNF signalling are associ-
ated with depression-related behaviours in women 
only (Lee et al. 2007; Monteggia et al. 2007), 
generalization to men is questionable. 
  Furthermore, mixed results have been reported 
for associations between serum BDNF levels and age 
(Lang et al. 2004; Aydemir et al. 2007), although the 
only study conducted in older people found decreased 
BDNF levels with age (Ziegenhorn et al. 2007). 
Furthermore, in dementia patients, lower BDNF 
serum levels have been associated with a higher risk 
of neurodegenerative processes (Yasutake et al. 
2006), which is in line with the neuroprotective 
effects of BDNF. The correlation between oestrogen 
and BDNF levels may not necessarily offer an expla-
nation for the potential sex differences (Monteleone 
et al. 2007), but may also result in sex-speciﬁ  c 
correlations with age due to a post-menopausal drop 
in oestrogen levels (Simpkins and Singh 2008). 
  To be able to study age, sex and depressive symp-
toms as determinants of serum BDNF levels in 
humans, potential confounders have to be taken into 
account. Not only is BDNF increasingly considered 
a neurotrophin, it is also seen as an immunotrophin, 
epitheliotrophin and metabotrophin (Chaldakov et al. 
2007), which would explain why, besides psychiatric 
and neurodegenerative diseases, somatic illnesses 
have also been related to BDNF. Somatic conditions 
that have been shown to correlate with BDNF levels 
mainly concern cardiovascular disease or cardiovas-
cular risk factors (Ejiri et al. 2005; Geroldi et al. 
2006; Hristova and Aloe, 2006; Suwa et al. 2006; 
Krabbe et al. 2007; Fujinami et al. 2008), which is 
not surprising given that serum levels may be affected 
by lifestyle factors such as chronic or excessive 
alcohol use, lack of physical exercise and smoking 
(Chan et al. 2008; Montag et al. 2008; Tang et al. 
2008; Currie et al. 2009; Umene-Nakano et al. 
2009). One study has further identiﬁ   ed a diurnal 
variation in BDNF levels, suggesting the need to cor-
rect for time of sampling (Piccinni et al. 2008). 
  Taken together, there is ample evidence to suggest 
that BDNF is linked to a variety of molecular abnor-
malities underlying neuropsychiatric and neurodegen-
erative diseases. However, the ﬁ  ndings to date were 
obtained in relatively small and mostly clinical 
samples and are thus of modest statistical power and 
limited generalizability, without large-scale studies 
having replicated the data in non-clinical cohorts or 
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(triglyceride concentration      150 mg/dl [1.695 
mmol/l]) or speciﬁ  c medication for this lipid abnor-
mality, HDL cholesterol      40 mg/dl [1.03 mmol/l] 
in men and      50 mg/dl [1.29 mmol/l] in women or 
speciﬁ  c medication for this lipid abnormality, and 
fasting plasma glucose      100 mg/dl [5.6mmol/l] or 
previously diagnosed type II diabetes mellitus. Sys-
tolic and diastolic blood pressure were measured 
using an oscillometric sphygmomanometer (Criti-
con model no. 1846, Criticon Inc., Tampa, FL, 
USA), while waist circumference was determined at 
the level of the umbilicus and triglycerides (TG) and 
glucose concentrations established using commer-
cially available enzymatic reagents (AEROSET  ®   
System, Abbott, Chicago, IL). 
  Smoking status, physical activity and alcohol use 
were assessed during a short interview and all oper-
ationalized as dichotomies: current smoker versus 
non-smoker, 0  –  1 h of weekly physical (sport) activity 
versus 2 h or more (Stampfer et al  .   2000), and severe 
(     21 units for males and      14 units for females) 
versus non-severe use of alcohol, respectively. 
  As to chronic diseases, we screened for coronary 
artery disease (CAD) and other somatic conditions. 
CAD was deﬁ  ned and coded as present/absent based 
on a history of treated angina pectoris, myocardial 
infarction, a history of percutaneous transluminal 
coronary angioplasty or coronary artery bypass 
grafting. Other solitary or comorbid somatic condi-
tions were lumped together as they have never been 
linked to BDNF serum levels before. All were coded 
as present/absent, with somatic disease being opera-
tionalized as receiving treatment for rheumatic dis-
order (or arthritis), COPD, liver disease, kidney 
disease or a history of or current treatment for 
Crohn  ’  s disease or ulcerative colitis. Dementia was 
determined by self-report and, if reported, cross-
checked against the respondents  ’   medical records.     
  Data analysis 
  The BDNF levels were normally distributed in our 
sample. Levels above three standard deviations (SDs) 
were trimmed to the 3-SD value, i.e. 17.8 ng/ml, 
which occurred in 11 (0.9%) cases. 
  Respondents with more than two missing item 
scores on the BDI were excluded from the analyses. 
In case of one or two missing items on the BDI, miss-
ings were replaced by the series mean rounded to the 
nearest full digit (necessary in 73 subjects (5.7%); in 
total 88 of 25.830 (  ≈  0.3%) items). Imputation by 
the series mean is a reliable method with up to 10% 
missing items (Shrive et al. 2006). Since the BDI 
scores showed a skewed distribution (skewness: 1.52, 
kurtosis: 3.01), we used the log-transformed BDI scores 
in all analyses (skewness: 0.32, kurtosis:   –  0.50).              
(i.e. without subsequent dilution) on the preceding 
day, or from those derived after acid treatment con-
ducted the day of the BDNF measurement. The 
serum samples used in our pilot study were stored 
samples of six individuals that did not participate in 
the present study. The samples  ’   coefﬁ  cients of vari-
ance ranged from 2.9 to 8.1%. To gauge the intra-
assay variance for the present study, we analyzed two 
of our current samples on two different plates on the 
same day. The resultant coefﬁ  cients of variance of 
0.0 and 3.1% were both well below the maximum 
intra-assay variance of 8.8% as speciﬁ  ed by the man-
ufacturer. Greiner Bio-One high afﬁ  nity  96-well 
plates were used and the resulting absorbance 
was read in duplicate using a Biorad Benchmark 
microplate reader at 450 nm. BDNF protein levels 
were expressed in ng/ml.     
  Depressive symptoms 
  Depressive symptoms were assessed using the Beck 
Depression Inventory (BDI), a 21-item self-report 
questionnaire with excellent psychometric charac-
teristics (Beck and Steer, 1984). Each item is rated 
on a 4-point scale, with 0 reﬂ  ecting the absence of 
symptoms and 1  –  3 increasing levels of symptom 
severity. The BDI yields a total score ranging from 0 
to 63. Individual items of the BDI can be considered 
to belong to a cognitive subscale or a somatic sub-
scale (Beck and Steer 1987). Separate sum scores for 
both of these subscales were calculated. History of 
depression was assessed by a self-report question 
with a dichotomous outcome (yes/no).     
  Possible determinants         
  Potential confounders of any associations between 
BDNF levels and depression were determined based 
on previous studies and categorized in four groups: 
sampling characteristics, sociodemographic vari-
ables, health indicators and chronic diseases. 
  Sampling characteristics were the time of blood 
withdrawal and the number of months the serum 
was stored at   –  80  °  C. Age, sex, and marital status 
were taken as the sociodemographic variables of 
interest. Health indicators were the presence of met-
abolic syndrome (MS), smoking status, physical 
activity, and alcohol use. MS (deﬁ  ned according to 
the International Diabetes Federation criteria (IDF 
2009) was determined by physical examination and 
fasting vena puncture. Participants were diagnosed 
with the syndrome if they had central obesity (BMI 
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diagnosed with dementia. Table I gives an overview 
of the characteristics of all participants. 
  The ﬁ   rst multiple regression models in which 
every domain was entered separately yielded three 
signiﬁ  cant determinants. As can be seen in Table II, 
signiﬁ  cantly lower BDNF levels were found when 
measured in the afternoon (  B           –  0.57, 95% CI 
  –  1.03 to   –  0.12;   t           –  2.46,   P         0.014), with higher 
age in female respondents (age  –  sex interaction 
term:   B           –  0.15, 95% CI   –  0.21 to 0.09;   t           –  4.73, 
  P         0.001; see also see Figure 1), and non-smokers 
(  B          0.87, 95% CI 0.37 to 1.38;   t         3.38,   P         0.001). 
Although the other somatic co-morbidity variable 
remained under the   P         0.15 level, it did not reach 
statistical signiﬁ  cance at the   P         0.05 level (  B         0.47, 
95% CI   –  0.76 to 1.02;   t         1.69,   P         0.091). 
  As Table III shows, our ﬁ  nal model uncovered a 
signiﬁ  cantly lower in BDNF levels with higher BDI 
sum scores (  B           –  0.56, 95% CI   –  1.1 to   –  0.02; 
  t           –  2.03,   P         0.042). Re-analysis of the age effect 
stratiﬁ  ed for a low BDI (     14) and high BDI (     14) 
score revealed that the age effect for women was 
present and statistically signiﬁ  cant in both groups 
(  B           –  1.25, 95% CI   –  1.76 to   –  0.75;   t           –  4.86,   
P         0.001, respectively,   B           –  1.59, 95% CI   –  3.13 
to   –  0.004;   t           –  2.07,   P         0.04) and also absent in 
both males with high BDI (     14) and a low BDI 
(      14) sum scores (both   P   values       0.61).          
  Separate evaluation of the different subscales of 
the BDI, revealed that the cognitive subscale was 
signiﬁ   cantly associated with serum BDNF levels 
(  B           –  0.544, 95% CI   –  1.07 to   –  0.016;   t           –  2.02, 
  P         0.043), whereas the somatic subscale was not 
  Pearson  ’  s correlation coefﬁ  cients were used for all 
univariate analyses. We performed multiple linear 
regression analyses to evaluate the independent 
determinants of serum-BDNF. To facilitate the inter-
pretation of the age  –  sex interaction, rather than tak-
ing their absolute ages, we calculated and included 
the deviation from the mean, so that the participants  ’   
ages were centred around the sample  ’  s mean age. 
First, we generated multivariate models within 
each domain by entering sampling characteristics, 
sociodemographic characteristics, health indicators 
and health-status variables in four separate models. 
Subsequently, the independent predictors from all 
domain-speciﬁ   c models with   P   values lower than 
0.15 were ﬁ  tted into a ﬁ  nal multivariate model using 
an enter method. The association between serum 
BNDF level and depression was examined by adding 
current depressive symptoms as indicated by the log-
transformed BDI sum score to the ﬁ  nal model. All 
analyses were conducted with SPSS, version 16.0.       
  Results 
  Of the 1517 older adults who consented to partici-
pate in the study of non-invasive measurements of 
atherosclerosis, 59 were excluded from our study 
because they were currently using antidepressants. Of 
the 1458 eligible subjects a further 228 (15.6%) were 
excluded due to missing data: non-return of the 
postal questionnaire containing the BDI (  n         175); 
three or more missing BDI item scores (  n         37); 
violation of the rules for a reliable MS or BDNF 
measurement (i.e. having smoked prior to testing 
(  n         3); non-adherence to the pretest fasting protocol 
(  n         2); non-adherence to abstinence from lipid-
lowering medication ( n         5)); unavailability of serum-
BDNF values due to technical problems (  n         6). 
  The subjects with missing data (228/1458, 15.6%) 
differed from the ﬁ  nal study sample (  n         1230) with 
respect to age (62.0 vs. 61.2 years,   t  (df 1456)      2.17, 
  P         0.03), somatic comorbidity (3 vs. 11%, 
  t  (df 1456)         –  3.93,   P         0.001), level of alcohol use 
(severe 6 vs. 12%,   t  (df 1455)         –  2.25,   P         0.012), 
and smoking (current smokers 26 vs. 16%,   t  (df 
1454)       3.46,   P         0.001). The serum BDNF levels 
obtained in the excluded participants with non-
missing serum-BDNF levels, however, did not differ 
from those found in the study population. 
  The ﬁ   nal study population (  n         1230) had a 
mean age of 61.1 years (SD       5.9 years) with ages 
ranging from 50 through to 72 years. Of this group 
614 participants (49.9%) were female. The BDI 
median score was 4 (interquartile range 2  –  7, 
range 0  –  29) and the mean serum BDNF 7.79 ng/ml 
(SD       3.32 ng/ml). None of the participants was 
    Table I. Population characteristics.   
N   1230
BDNF (ng/ml, SD) 7.79 (3.32)
BDI sum score (median, IQR) 4 (2  –  7)
% with history of depression (  n  ) 16.9 (208)
  Sampling 
% sampling in the morning (  n  ) 79.2 (974)
Months in storage (SD) 23.7 (9.5)
  Sociodemographics 
% female (  n  ) 49.9 (614)
Age (mean in years, SD) 61.2 (5.9)
% living alone (  n  ) 21.4 (263)
  Health indicators 
% current smoker (  n  ) 16.1 (195)
% severe alcohol use (  n  ) 11.8 (145)
% 2 or more hours of physical activity p/w (  n  ) 36.6 (450)
  Disease 
% metabolic syndrome (  n  ) 27.8 (342)
% coronary artery disease (  n  ) 6.7 (83)
% somatic co-morbidity other than CAD (  n  ) 11.0 (135)
      BDNF, brain-derived neurotrophic factor; SD, standard deviation; 
BDI, Beck Depression inventory; IQR, interquartile range; CAD, 
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values in older women relative to the levels obtained 
in age-matched men (Karege et al. 2002a; Laske 
et al. 2007). Given that the effects of sex and age 
were quite small, most previous studies were prob-
ably underpowered, preventing detection of signiﬁ  -
cant sex differences (Laske et al. 2007). Several, 
mostly underpowered, studies indeed failed to ﬁ  nd 
an age effect (Aydemir et al. 2007; Shimizu et al. 
2003), while a small-scale study of healthy adult 
volunteers (mean age 41.1 years old) even reported 
increased BDNF levels with age (Lang et al. 2004). 
(  B           –  0.312, 95% CI   –  1.03 to 0.406;   t           –  0.85,   
P         0.39).              
  Subsequent analysis, also revealed that persons 
with a self-reported history of depressive illness have 
lower serum BDNF levels (B         –  0.606, 95% CI 
  –  1.05 to   –  0.163;   t           –  2.68,   P         0.007), when cor-
rected for potential confounders. Including a history 
of depressive illness and current depressive symp-
toms in one multivariate regression analysis led to 
collinearity problems. Therefore, we could not dis-
entangle whether low serum BDNF levels reﬂ  ect a 
state or trait characteristic.                  
  Discussion 
  To our knowledge, this is the ﬁ  rst study of a large 
community sample of middle-aged and older people 
providing clear evidence that BDNF levels signiﬁ  -
cantly decline in women with increasing age, while 
levels remain stable in men (see Figure 1). Moreover, 
and equally important, even after controlling for age 
and gender effects our analysis showed that BDNF 
levels are lower with increased levels of depressive 
symptoms. These effects remained signiﬁ  cant even 
after correction for time of sampling and smoking, 
two important confounders.   
  BDNF and sex and age 
  If the interaction is not taken into account, the sex-
speciﬁ  c decline of BDNF levels with age may result 
in opposite sex effects, with higher BDNF values 
being found in younger women and lower BDNF 
    Table II. Results of the univariate and multivariate analyses per category.   
Univariate Multivariate
  r  P   B  95% CI of   B SE   β   t  P
  Model 1 (Sampling variables) 
Time of day (0       AM, 1       PM)   –  0.069 0.008   –  0.573   –  1.03   –     –  0.12 0.233   –  0.070   –  2.459 0.014
Time in storage (days)   –  0.014 0.31 0.000 0.00   –   0.00 0.000   –  0.017   –  0.610 0.54
  Model 2 (Demographic variables) 
Age (years deviating from mean age)   –  0.112      0.001 0.0012   –  0.03   –   0.06 0.022 0.022 0.561 0.58
Sex (0       male, 1       female) 0.035 0.11 0.181   –  0.19   –   0.55 0.190 0.027 0.956 0.34
Interaction age       sex n/a n/a   –  0.151   –  0.21   –     –  0.09 0.032   –  0.187   –  4.734      0.001
Marital status (1       living alone, 2       living together)   –  0.041 0.08   –  0.276   –  0.73   –   0.18 0.231   –  0.034   –  1.199 0.23
  Model 3 (Health variables) 
Alcohol use (male     21/week; female       14/week)   –  0.028 0.16   –  0.401   –  0.98   –   0.17 0.294   –  0.039   –  1.362 0.17
Current smoker (0       no, 1       yes) 0.094      .001 0.872 0.37   –   1.38 0.258 0.097 3.379 0.001
Physical activity (0             1 hrs/week, 1            2 hrs/week)   –  0.023 0.22   –  0.082   –  0.47   –   0.30 0.197   –  0.012   –  0.416 0.68
  Model 4 (Disease variables) 
Metabolic Syndrome (IDF) (0       no, 1       yes) 0.007 0.39 0.035   –  0.32   –   0.39 0.182 0.005 0.191 0.85
Coronary artery disease (0       no, 1       yes) 0.011 0.35   –  0.043   –  0.71   –   0.63 0.341   –  0.003   –  0.126 0.90
Somatic co-morbidty other than CAD (0       no, 1       yes) 0.044 0.05 0.473   –  0.08   –   1.02 0.280 0.044 1.690 0.09
        R  , Pearson  ’  s correlation coefﬁ  cient;   B  , regression coefﬁ  cient; CI, conﬁ  dence interval; SE, standard error of the mean;   β  , standardized 
correlation coefﬁ  cient; CAD, coronary artery disease.     
   
    Figure 1.         Interactice effect of age and gender on serum BDNF 
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  BDNF and determinants 
  Serum BDNF levels were signiﬁ  cantly lower if blood 
was drawn in the afternoon. Diurnal variations 
have previously been found for BDNF plasma level 
(Piccinni et al. 2008). However, since we only 
recorded whether sampling occurred before (AM) or 
after noon (PM), we are unable to describe the vari-
ation in BDNF levels in more detail. Of the health-
behaviour variables, smoking was the only factor to 
show an association with BDNF levels (elevated levels 
in smokers). Interestingly, nicotine use has been 
linked to a decreased risk of dementia (Wang et al. 
2009), which might point to a mediating role for 
BDNF. Nonetheless, as a case  –  control study (  n         40) 
reported reverse effects of smoking on plasma BDNF 
levels (Kim et al. 2007), additional research is neces-
sary to establish whether this apparent inconsistency 
might be explained by altered platelet functioning in 
smokers, which would affect BDNF serum but not 
plasma levels (Nowak et al. 1987).     
  Strengths and weaknesses 
  It remains unclear whether lower levels of circulating 
BDNF result from lower brain BDNF concentra-
tion. Although high correlations between serum 
BDNF and cerebral-BDNF levels have been shown 
in animal models (Karege et al. 2002b), this has, 
thus far, not been conﬁ   rmed in humans. Despite 
well-established ﬁ  ndings of lower serum BDNF in a 
depressed population, inferences of BDNF as a 
causal marker for depression are still limited. Plate-
lets have been described as one of the many sources 
of BDNF: the factor is released by platelets during 
the clotting process resulting in a 200-fold increase 
in BDNF serum relative to the levels found in plasma 
(Rosenfeld et al. 1995). As BDNF in platelets does 
not originate from megakaryocytes or other precur-
sor cells of the mature platelet (Fujimura et al. 2002), 
it is likely that most of the BDNF in human platelets 
is sequestered from blood (Nakahashi et al. 2000). 
Differences in platelet functioning as described in 
depressed patients (Ziegelstein et al. 2009), therefore, 
The only study conducted in older adults, however, 
did show lower serum BDNF levels with higher age 
(Ziegenhorn et al. 2007), a ﬁ  nding we were able to 
replicate and extend by showing an interaction 
between age and sex effects. As the age effect in 
women was also present in subjects with a high score 
on BDI (     14), this should also be taken into account 
in studies with a clinically depressive sample. A pos-
sible explanation for the age  –  sex interaction with 
respect to BDNF serum levels might be its relation-
ship with gonadal hormones, as BDNF synthesis is 
induced by estrogen (Nagahara et al. 2009) and high 
correlations between plasma-BDNF and oestrogen 
levels have been reported in humans (Monteleone 
et al. 2007). Moreover, both oestrogen depletion and 
low serum BDNF levels have been identiﬁ  ed as risk 
factors for Alzheimer  ’  s disease (Craig and Murphy 
2009). Despite the cross-sectional character of the 
studies reviewed, the hypothesis may be put forward 
that a post-menopausal drop in oestrogen levels 
results in reduced BDNF levels, explaining the 
increased vulnerability of middle-aged and older 
women to neurodegenerative disease (Craig and 
Murphy 2009; Reitz et al. 2010). This hypothesis 
should however be tested in longitudinal studies.     
  BDNF and depression 
  Our results extend previous studies reporting lower 
serum BDNF levels in patients with major depres-
sive disorder (MDD) relative to healthy controls 
(Brunoni et al. 2008; Sen et al. 2008; Molendijk 
et al  .   2010) to a broader, continuous relationship 
between BDNF levels and depressive symptoms in 
a community sample. An association between BDNF 
serum levels and severity of depressive symptoms 
has also been identiﬁ  ed in two studies of patients 
with depressive disorder (Shimizu et al. 2003; Gonul 
et al. 2005), although one other study reported a 
negative result (Lang et al. 2006). Taken together, 
the ﬁ   ndings suggest a linear association between 
the two variables that is independent of the current 
categorical boundaries for depression.     
          Table III. Final model with BDI scores corrected for potential confounders. 
  B  95% CI of BS E  β   t p
Constant 7.959 7.6   –   8.4 0.208 38.277 .000
BDI (log-transformed) –0.607   –  1.13   –     –  0.09 0.265   –  0.060   –  2.296 .022
Age (yrs) –0.006   –  0.05   –   0.03 0.020 0.011   –  0.304 .761
Sex (0       male; 1       female) 0.293   –  0.04   –   0.63 0.170 .045 1.724 .085
Interaction age       sex –0.110   –  0.17   –     –  0.05 0.028   –  0.138   –  3.873 .000
Time of day (0       AM; 1       PM) –0.405   –  0.80   –     –  0.01 0.204   –  0.050   –  1.985 .047
Current smoker (0       no; 1       yes) 0.613 0.19   –   1.06 0.215 0.072 2.843 .005
Somatic co-morbidity (0       no; 1       yes) 0.515   –  0.03   –   1.06 0.278 0.047 1.857 .063
        B  , regression coefﬁ  cient; CI, conﬁ  dence interval; SE, standard error of the mean;   β  , standardized correlation coefﬁ  cient.          Determinants of serum brain-derived neurotrophic factor            45
factors. For example, BDNF might be implicated in 
the increased vulnerability to dementia in post-
menopausal women. Here also, further corrobora-
tion of the interplay of gonadal hormones and BDNF 
on psychiatric illnesses and neurodegenerative 
diseases is warranted.     
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